Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Tumour lysis syndrome
ADR ID BADD_A04401
ADR Hierarchy
14      Metabolism and nutrition disorders
14.05      Electrolyte and fluid balance conditions
14.05.01      Electrolyte imbalance NEC
14.05.01.004      Tumour lysis syndrome
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.32      Neoplasm related morbidities
16.32.03      Oncologic complications and emergencies
16.32.03.002      Tumour lysis syndrome
Description A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia. [MeSH]
MedDRA Code 10045170
MeSH ID D015275
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Tumor lysis syndrome | Tumour lysis syndrome | Laboratory tumour lysis syndrome | Clinical tumour lysis syndrome | Laboratory tumor lysis syndrome | Clinical tumor lysis syndrome | Tumor Lysis Syndrome | Syndrome, Tumor Lysis | Syndromes, Tumor Lysis | Tumor Lysis Syndromes | Tumour Lysis Syndrome | Syndrome, Tumour Lysis | Syndromes, Tumour Lysis | Tumour Lysis Syndromes
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01601Olaparib0.000112%
BADD_D01609Omacetaxine mepesuccinate0.000112%
BADD_D01629Osimertinib0.000112%
BADD_D01633Oxaliplatin0.000504%
BADD_D01653Paclitaxel0.000280%
BADD_D01687Pazopanib0.000616%
BADD_D01730Pentostatin0.000112%
BADD_D01798Pomalidomide--
BADD_D01799Ponatinib0.000280%
BADD_D01814Pralatrexate0.000168%
BADD_D01831Prednisolone0.000245%
BADD_D01917Rasburicase--
BADD_D01922Regorafenib0.000280%
BADD_D01964Romidepsin0.000112%
BADD_D01978Ruxolitinib0.000412%
BADD_D02058Sorafenib0.000336%
BADD_D02100Sunitinib0.001175%
BADD_D02192Thalidomide0.000530%
BADD_D02344Vemurafenib0.000336%
BADD_D02345Venetoclax0.006100%
BADD_D02360Vincristine0.000280%
BADD_D02361Vincristine sulfate--
BADD_D02365Vismodegib0.000112%
BADD_D02482Acalabrutinib0.001679%
BADD_D02483Ribociclib0.000168%
BADD_D02504Lorlatinib0.000112%
BADD_D02505Gilteritinib0.000224%
BADD_D02509Brigatinib0.000112%
BADD_D02517Enasidenib0.000224%
BADD_D02566Lurbinectedin0.000336%
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages